Physician profile
Eric John Trueblood
NPI 1215924675
$5,116.40
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $603 · 2021: $676 · 2022: $855 · 2023: $866 · 2024: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.12 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,035.70 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.09 | 2019-2024 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $271.94 | 2021-2023 | |
| Insmed, INC. | $265.16 | 2019-2024 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $228.87 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $151.82 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $128.73 | 2023-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $126.71 | 2020-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $124.33 | 2022-2023 | Uptravi, Opsumit |
| Boston Scientific Corporation | $114.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $86.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.26 | 2020-2021 | |
| Grifols USA, LLC | $67.74 | 2020-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $54.57 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.72 | 2020-2024 | Tezspire, Tavneos |
| Resmed Corp | $52.67 | 2022-2023 | |
| Cook Medical LLC | $46.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $41.91 | 2022-2023 | Austedo Xr, Airduo Digihaler |
| Shire North American Group INC | $41.69 | 2019 | |
| Inspire Medical Systems, INC. | $41.10 | 2024 | Inspire |
| Mallinckrodt Hospital Products INC. | $36.71 | 2024 | Acthar |
| Chiesi USA, INC. | $31.75 | 2020-2021 | |
| Genentech USA, INC. | $29.08 | 2020-2023 | Xolair |
| Tetraphase Pharmaceuticals, INC. | $28.82 | 2019 | |
| Biomerieux INC | $28.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Philips North America LLC | $19.99 | 2021 | |
| Sobi, INC | $18.08 | 2024 | |
| Baxter Healthcare | $16.07 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $16.05 | 2019 | |
| Axsome Therapeutics, INC. | $15.05 | 2023 | Sunosi |
| Pulmonx Corporation | $14.99 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Astellas Pharma US INC | $14.06 | 2019 | |
| Nabriva Therapeutics, Plc | $11.60 | 2020 | |
| Circassia INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Trueblood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.